A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

A Phase I/II Dose Escalation and Expansion Study to Evaluating the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.

Inclusion Criteria:

• Subjects who fully understood this trial and voluntarily signed the informed consent form;
• Men or women ≥ 18 years old;
• ECOG Performance Status (PS) 0 or 1;
• Life expectancy > 3 months.

Exclusion Criteria:

• Received any treatment with inhibitors against KRAS G12C mutation at any time, e.g., AMG 510, MRTX 849, etc.;
• Patients requiring medications that can potentially prolong QTc interval;
• Other conditions that the investigator considers to be unsuitable for participation in this study.